US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

271.23

+6.212.34%

Post-market: 271.230.00000.00%19:30 EDT

Volume:37.71K

Turnover:10.15M

Market Cap:2.94B

PE:31.74

High:271.23

Open:268.20

Low:267.24

Close:265.02

52wk High:274.99

52wk Low:173.98

Shares:10.85M

Float Shares:10.85M

Volume Ratio:1.13

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.06

PE(LYR):7.18

Loading ...

Overview Company News Filings

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares

Bruker Nano Exec VP Mark Munch Sells 2,000 Bruker Shares for $105,740

Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares

Alkermes Appoints Anne Whitaker to Board of Directors

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

THOMSON REUTERS

Brookfield Strikes $2.9 Billion Cash Deal for Australian Plumbing Supplier Reliance Worldwide

Fourth Bid Succeeds: Brookfield Clinches $2.9 Billion Deal for Australian Pipe Maker RWC at 32% Premium

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

MT Newswires Live

Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Veracyte Completes Convergent Genomics Acquisition to Expand Urology

Veracyte Buys Convergent Genomics

MT Newswires Live

Veracyte acquires Convergent Genomics for $150M in cash upfront

Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

THOMSON REUTERS

Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments

THOMSON REUTERS

Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028

THOMSON REUTERS

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/FBT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":271.23,"timestamp":1789675200000,"preClose":265.02,"halted":0,"volume":37714,"hourTrading":{"tag":"盘后","latestPrice":271.23,"preClose":271.23,"latestTime":"19:30 EDT","volume":1252,"amount":339578.81,"timestamp":1789687805610,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.023432193796694728,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Closed","change":6.21,"latestTime":"09-17 16:00:00 EDT","open":268.2,"high":271.23,"low":267.24,"amount":10145857.994,"amplitude":0.015055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.02,"sharesOutstanding":11450002,"nav":264.91,"aum":2887519529.82,"bidAskSpread":0.00099,"preHourTrading":{"tag":"盘前","latestPrice":265.02,"preClose":265.02,"latestTime":"08:21 EDT","volume":2,"amount":530.04,"timestamp":1789647687231,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":271.23,"preClose":271.23,"latestTime":"19:30 EDT","volume":1252,"amount":339578.81,"timestamp":1789687805610,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.131615,"impliedVol":0.2321,"impliedVolPercentile":0.8127},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.131615,"shares":10850002,"dividePrice":0,"high":271.23,"amplitude":0.015055,"preClose":265.02,"low":267.24,"week52Low":173.975,"pbRate":"1.06","psRate":"709.93","week52High":274.99,"institutionHeld":0,"latestPrice":271.23,"eps":8.545272,"divideRate":0,"volume":37714,"delay":0,"ttmEps":8.545272,"open":268.2,"prevYearClose":206.52,"prevWeekClose":261.85,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":262.28,"twentyDayClose":271.87,"sixtyDayClose":230.605},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668991067","title":"FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668991067","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668991067?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:35","pubTimestamp":1789670130,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Fayuvi, which it calls “the first treatment for pediatric patients with mucopolysaccharidosis type I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","FBT","IBBQ","BK4585","TBXU","BK4588","LABU","CNCR","IBB","SYNB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996274","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996274?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS), Twist Bioscience (TWST) and Medpa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","IBRN","XBI","XLV","FBT","ALKS","BK4139","BK4137","LU2065171311.SGD","LU2065169927.USD","ARKG","BK4588","BK4581","LABU","PSCH","MEDX","TWST","WDNA","HCSG","MEDP","IDNA","LU2065170008.USD","PSIL","BK4121","LU2065171402.SGD","LU0128526141.USD","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668115964","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668115964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668115964?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:50","pubTimestamp":1789645810,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-veracyte-vcyt-iqvia-holdings-iqv-and-chemed-che-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-veracyte-vcyt-iqvia-holdings-iqv-and-chemed-che-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2413666004.HKD","LU0130518102.USD","IE00BLDYK493.USD","LU0528227936.USD","LU0648001328.SGD","LU1165135440.EUR","LU1201861165.SGD","XBI","XLV","FBT","LU0130103400.USD","LU2413665964.HKD","LU1620156213.USD","BK4139","BK4137","LU0477156797.USD","LU0980610538.SGD","LU1791710400.SGD","EKG","IE00B64QTZ34.USD","BK4588","LU0130102774.USD","LU0130517989.USD","LU0882574055.USD","LU1201861249.SGD","LU1596574779.USD","VCYT","BK4581","LABU","LU0648000940.SGD","LU1721427968.SGD","LU1791710582.SGD","HCSG","LU0477156953.USD","LU1620156130.USD","HEAL","IQV","LU1989764664.SGD","CHE","BK4530","BK4121","LU1261432733.SGD","BK4196","LU1989764748.USD","LU0128526141.USD","LU0029874061.USD","BK4585","LU1543694498.USD","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","GDOC","GNOM","LGVN","FBT","BK4139","BK4588","TBXU","LFSC","BK4585","SYNB","NVIB","IBBQ","MEDX","IBB","CNCR","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668693589","title":"Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668693589","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668693589?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:31","pubTimestamp":1789590707,"startTime":"0","endTime":"0","summary":"Corcept director James N. Wilson disposes of $1.11 million in common sharesCorcept director James N. Wilson reported selling 10,000 common shares on Sept. 15, 2026.Sales prices ranged from USD 110.27 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL5LXKps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","FBT","PSCH","LU0566484027.USD","LU1559883803.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933265","title":"Bruker Nano Exec VP Mark Munch Sells 2,000 Bruker Shares for $105,740","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933265","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933265?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:16","pubTimestamp":1789589780,"startTime":"0","endTime":"0","summary":"Bruker Nano Exec VP Mark Munch sells 2,000 Bruker shares for $105,740Mark Munch, executive vice president and president of Bruker Nano, sold 2,000 Bruker common shares at USD 52.87 on Sep. 15, 2026.He","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL78KKS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Bruker Nano Exec VP Mark Munch Sells 2,000 Bruker Shares for $105,740","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","FBT","TINY","BK4121","LU0757428866.USD","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668393317","title":"Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668393317","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668393317?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:09","pubTimestamp":1789589347,"startTime":"0","endTime":"0","summary":"Veracyte director Jens Holstein disposes of USD 204,747 common sharesVeracyte director Jens Holstein sold 5,000 common shares on Sept. 14, 2026 at a weighted average price of $40.95.Holdings fell to 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL3rcYDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607455","title":"Alkermes Appoints Anne Whitaker to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607455","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607455?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556448,"startTime":"0","endTime":"0","summary":"Alkermes appoints Anne Whitaker to board of directorsAlkermes appointed Anne C. Whitaker as an independent director to its board.Whitaker is a biopharmaceutical executive with commercial, operational,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL86gXCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","FBT","PSCH","MEDX","BK4139","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607123","title":"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607123?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA78XSXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","PSIL","BK4139","FBT","MEDX","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117818184","title":"Brookfield Strikes $2.9 Billion Cash Deal for Australian Plumbing Supplier Reliance Worldwide","url":"https://stock-news.laohu8.com/highlight/detail?id=1117818184","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117818184?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:40","pubTimestamp":1789555227,"startTime":"0","endTime":"0","summary":"Brookfield Asset Management has sealed an all-cash acquisition agreement for Reliance Worldwide, valuing the plumbing fittings manufacturer at an enterprise worth of $2.9 billion. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","TINY","BK4121","LU0757428866.USD","BRKR","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161539100","title":"Fourth Bid Succeeds: Brookfield Clinches $2.9 Billion Deal for Australian Pipe Maker RWC at 32% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=1161539100","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161539100?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:34","pubTimestamp":1789526059,"startTime":"0","endTime":"0","summary":"Brookfield Asset Management has reached an agreement to acquire Reliance Worldwide Corp. in an all-cash transaction that values the Australian piping products manufacturer at roughly A$4.1 billion...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TINY","BK4121","BRKR","LU0757428866.USD","LU1815336091.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667162504","title":"Veracyte Adds Another Stream to Bladder Franchise, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667162504","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667162504?lang=en_us&edition=fundamental","pubTime":"2026-09-15 23:58","pubTimestamp":1789487931,"startTime":"0","endTime":"0","summary":"Veracyte  is adding an adjacent product to its bladder franchise following its acquisition of Convergent Genomics, UBS Securities said in a Monday note.\"We view this as a strategic move by VCYT to expand menu ofofferings into urine-based monitoring,\" the note said.Late Monday, the company reported the Convergent acquisition for $150 million upfront, plus up to $30 million in milestone payments tied to reimbursement.The deal adds Convergent's UroAmp urinary tumor DNA platform, the note said, adding that it has been clinically validated in non-muscle invasive bladder cancer for therapy-response monitoring and post-treatment surveillance.\"While revenue contribution is likely a few years away, the addition of UroAmp reinforces our Buy rating and our view that VCYT has multiple growth levers capable of supporting long-duration double-digit revenue growth,\" the report said.Price: 41.18, Change: -0.03, Percent Change: -0.07","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","VCYT","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667444786","title":"Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667444786","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667444786?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (\"Legend Biotech\" or the \"Company\"), a global leader in cell therapy, today announced that its Board of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","BK4022","BK4585","BK4505","CANC","XBI","MEDI","R","IBB","GNOM","LEGN","CNCR","TBXU","FBT","SYNB","BK4581","IBBQ","BK4588","BK4232","MEMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695415","title":"Veracyte Completes Convergent Genomics Acquisition to Expand Urology","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695415","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695415?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:31","pubTimestamp":1789417898,"startTime":"0","endTime":"0","summary":"Veracyte ( ($VCYT) ) has shared an update. On Sept. 14, 2026, Veracyte completed the acquisition of Convergent Genomics Inc., a bladder cancer-focu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veracyte-completes-convergent-genomics-acquisition-to-expand-urology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veracyte-completes-convergent-genomics-acquisition-to-expand-urology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","VCYT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667373695","title":"Veracyte Buys Convergent Genomics","url":"https://stock-news.laohu8.com/highlight/detail?id=2667373695","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667373695?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:22","pubTimestamp":1789417352,"startTime":"0","endTime":"0","summary":"Veracyte  said late Monday it has acquired Convergent Genomics for $150 million in upfront cash and up to additional $30 million tied to milestones over UroAmp reimbursement efforts.The company said the acquisition expands its urology diagnostics portfolio with a urinary tumor DNA testing platform.Veracyte said it contemplated Convergent's operating expenses in 2026 adjusted EBITDA outlook and is not updating its guidance.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBT","VCYT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695356","title":"Veracyte acquires Convergent Genomics for $150M in cash upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695356","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695356?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:10","pubTimestamp":1789416629,"startTime":"0","endTime":"0","summary":"Veracyte (VCYT) announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its propriet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veracyte-acquires-convergent-genomics-for-150m-in-cash-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veracyte-acquires-convergent-genomics-for-150m-in-cash-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667768693","title":"Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2667768693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667768693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693761","title":"Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693761?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667369376","title":"Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2667369376","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667369376?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","MEDX","IBRN","PSIL","FBT","BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}